PK and Safety of ALKS 5461 in Hepatic Impairment

Phase 1, open-label, single-arm trial of buprenorphine and samidorphan in major depressive disorder (MDD), sponsored by Alkermes. Primary endpoints: Area under the plasma concentration versus time curve from time 0 to infinity, Area under the plasma concentration versus time curve from time 0 to time of last measureable concentration and 1 more. Started May 2015; status: completed.